Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)?

insidermonkey.com · 2026-09-09

On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory.

TickrTrends take: Amgen currently trades at an overvalued assessment according to TickrTrends, placing it in a weaker relative position when compared to competitors like AstraZeneca that may offer stronger growth prospects. For investors focused on valuation metrics, the comparison raises questions about whether Amgen's current pricing reflects realistic expectations for its Healthcare sector operations. Monitoring Amgen's upcoming financial results and pipeline developments will be important for determining whether the overvaluation designation persists or adjusts as the company's growth trajectory becomes clearer.

Read the full story at insidermonkey.com →